Ribometrix

Ribometrix is a biotechnology company developing small molecule therapeutics that modulate RNA biology to treat human diseases.

[Ribometrix @Ribometrix]

Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer

https://t.co/BcApmgKfoR

[Ribometrix @Ribometrix]

New preclinical data presented at #ESMO24 support the potential of RBX-6610 as a potential treatment for NSCLC with KRAS mutations and reinforce its promise in multiple tumor types. Read more in our press release: https://t.co/tx2pcZdWyD

[Ribometrix @Ribometrix]

Proud to be sharing new data from our eIF4E program @myESMO Sep 15. We’ll have new efficacy data, incl. re-sensitization of tumors to the standard-of-care – so crucial in non-small cell lung cancer. #nsclc #esmo24 #rnatherapeutics More: https://t.co/46cphNXN8c

[Ribometrix @Ribometrix]

Today at #AACR24: new data across our portfolio, incl. POC of our small molecules to directly target c-MYC #RNA & reduce associated protein levels; and preclinical anti-tumor activity of our lead eIF4E preclinical candidate: https://t.co/EMAUYwk8So

[Ribometrix @Ribometrix]

Ribometrix will share new preclinical data at the 2024 #AACR Annual Meeting for our pioneering #RNA-modulating small molecule programs targeting elF4E and c-MYC. Learn more about our progress: https://t.co/FHiugCXWZ1

[Ribometrix @Ribometrix]

Today we are presenting new preclinical data supporting the potential of our eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS). More on our #SABCS23 data: https://t.co/tS4eEaarbg

[Ribometrix @Ribometrix]

Don’t miss our presentation of new preclinical data for our eIF4E inhibitor program at #SABCS23 in December. Data will show its potential in ER+ breast cancer, adding to our exciting early results in melanoma presented earlier this month. Learn more: https://t.co/FODuz8HOHL

[Ribometrix @Ribometrix]

Today we present preclinical data at the 2023 #SMRCONGRESS for our lead program targeting #RNA binding protein and regulator of oncogene translation, eIF4E. We’re excited to be advancing a set of small molecule eIF4E inhibitors toward IND-enabling studies: https://t.co/iLvoDl82Wq

[Ribometrix @Ribometrix]

We were honored to win a 2021 Life Sciences Award yesterday and we congratulate all of the other winners this year! We're proud to be part of such a thriving #TBJlifesci community.

[Triangle Business Journal @TriangleBIZJrnl]

Meet the winners in our 2021 Life Sciences Awards!​ https://t.co/zfjG2CQq2Q

[Pairwise @PairwisePL]

We’re honored to be named a 2021 @TriangleBIZJrnl #TBJlifesci Award winner! We believe in building a healthier world through better fruits and vegetables and are proud to call North Carolina’s intersection of technology and agriculture, Research Triangle Park, home.

[Ribometrix @Ribometrix]

We're very proud to announce that we won Best Early-Stage Product Development Company at the @TriangleBIZjrnl 2021 Life Sciences Awards. Congratulations to our amazing team! #TBJlifesci Read more: https://t.co/NAlMjI73af

[Ribometrix @Ribometrix]

Thanks @ArrakisTx, @Roche and @Genentech - we're excited to be creating a new generation of small molecule #RNA therapies with a superb class of partners and peers.

[Arrakis Therapeutics @ArrakisTx]

We congratulate our fellow RNA explorers at @Ribometrix on their collaboration with @Genentech and applaud our colleagues at @Roche for their growing commitment to developing a new class of medicines. #ExpeditionRNA https://t.co/sBBOzOPeOc

[Ribometrix @Ribometrix]

Today we announced a partnership with Genentech to discover and develop RNA-targeting small molecule therapeutic candidates against several targets. We will receive a $25M upfront payment and are eligible for potential milestone payments exceeding $1B.

https://t.co/nHYkpEpOfE

[Ribometrix @Ribometrix]

#Ribometrix is excited to add a new member to our leadership team, with the appointment of Barclay “Buck” Phillips as Chief Operating Officer and Chief Financial Officer: welcome, Buck! See the full Press Release here: https://t.co/6gjqyfPObn

[Ribometrix @Ribometrix]

If you are able to #donate, the Inter-Faith Food Shuttle can use your help! Donate here: https://t.co/Jn8tgR6dqD

[Ribometrix @Ribometrix]

The team at #Ribometrix wanted to do something help our #community during this difficult time. Employees donated money to the @FoodShuttle last week, and the company matched all employee dollars. In one week we raised $3,550! We love our #Triangle community! #wearefamily #RBX

[Ribometrix @Ribometrix]

#Ribometrix strives to provide a fun culture and we enjoy participating in #teambuilding events. Most recently we volunteered with #HabitatForHumanity. Working together to #giveback truly embodies our #mission and #corevalues. #teamworkmakesthedreamwork #powertoolsarefun

[Ribometrix @Ribometrix]

Exciting day, as we announce our partnership with Vertex Pharmaceuticals to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. Full PR here: https://t.co/8egycira4t

@VertexPharma
#RNA
#RNA-targeted_small_molecules
@TheRTP

[Ribometrix @Ribometrix]

Thrilled to announce $7.8 million in new funding from existing investors, the Dementia Discovery Fund and Illumina Ventures, and the appointment of Mike Clayman, M.D., as chairman of the board. https://t.co/gCWoDzWSrF
@DDF_VentureFund @illuminaventure #biotech #RNA @TheRTP

[Ribometrix @Ribometrix]

Welcome to John Reardon, our new CSO! He joins Don Hertzog, VP Drug Discovery, and Bill Janzen, VP Lead Discovery, who started in 2018. We are grateful to have these industry leaders join us in our endeavors to develop novel, RNA-targeting therapeutics.

https://t.co/x57f95xebN